X0508 4 2026-01-05 0001880438 AN2 Therapeutics, Inc. ANTX 0001949621 Eizen Joshua M C/O AN2 THERAPEUTICS, INC. 1300 EL CAMINO REAL, SUITE 100 MENLO PARK CA 94025 false true false false See Remarks false Common Stock 2026-01-05 4 S false 17923 1.0014 D 159430 D Common Stock 2026-01-06 4 S false 6931 1.012 D 152499 D Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2026. This transaction was executed in multiple trades at prices ranging from $1.001 to $1.003 per share. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Includes (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 60,000 RSUs which vest as follows: 25% of the RSUs vest on January 1, 2025, 50% of the RSUs vest on January 1, 2026, and 25% of the RSUs vest on July 1, 2026, (c) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, and (d) 58,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person's continuous service as of such date. Chief Operating Officer and Chief Legal Officer /s/ Lucy Day, Attorney-in-Fact for Joshua M. Eizen 2026-01-07